Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Sernova Corp (OP: SEOVF)
0.1438 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 3:40 PM EST, Nov 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 0.1438
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1438
Today's Range 0.1438 - 0.1438
52wk Range 0.1171 - 0.2170
Shares Outstanding 159,893,223
Dividend Yield N/A
Performance
YTD
+3.83%
+3.83%
1 Month
-16.25%
-16.25%
3 Month
-4.58%
-4.58%
6 Month
-27.74%
-27.74%
1 Year
-3.68%
-3.68%
Top News
More News
Sernova Announces Biotech Veteran as New Chief Financial Officer
Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow, CPA, CA, has joined Sernova as Chief Financial... Read More
from PR Newswire
InvestmentPitch Media Video Discusses Sernova Corp's Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes - Video Available on Investmentpitch.com
from Newsfile Corp News Releases
More News
Read More
Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes
category None
from TheNewswire.com - RSS (Media)
Sernova Renews Frontier Flex for Canadian Investor Relations and Marketing
category None
from TheNewswire.com - RSS (Media)
Sernova Completes Oversubscribed Private Placement of $4,684,564
category None
from TheNewswire.com - RSS (Media)
Sernova Announces Second Closing of Private Placement
category None
from TheNewswire.com - RSS (Media)
Sernova Announces First Closing of Private Placement
category None
from TheNewswire.com - RSS (Media)
Sernova Announces Up to $3 Million Private Placement Financing
category None
from TheNewswire.com - RSS (Media)
Sernova's Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data
category None
from TheNewswire.com - RSS (Media)
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes
category None
from TheNewswire.com - RSS (Media)
Sernova's Principal Investigator to Present Interim Data from the Company's Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant A
category None
from TheNewswire.com - RSS (Media)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.